Plants as Biofactories for Therapeutic Proteins and Antiviral Compounds to Combat COVID-19 DOI Creative Commons

Corbin England,

Jonathan TrejoMartinez,

Paula PerezSanchez

et al.

Life, Journal Year: 2023, Volume and Issue: 13(3), P. 617 - 617

Published: Feb. 23, 2023

The outbreak of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome 2 (SARS-CoV-2) had a profound impact on the world’s health and economy. Although end pandemic may come in 2023, it is generally believed that virus will not be completely eradicated. Most likely, become an endemicity. rapid development vaccines different types (mRNA, subunit protein, inactivated virus, etc.) some other antiviral drugs (Remdesivir, Olumiant, Paxlovid, has provided effectiveness reducing COVID-19’s worldwide. However, circulating SARS-CoV-2 been constantly mutating with emergence multiple variants, which makes control COVID-19 difficult. There still pressing need for developing more effective to fight against disease. Plants have promising production platform both bioactive chemical compounds (small molecules) recombinant therapeutics (big molecules). naturally produce diverse range as secondary metabolites, such alkaloids, terpenoids/terpenes polyphenols, are rich source countless compounds. can also genetically engineered valuable therapeutics. This molecular farming plants unprecedented opportunity vaccines, antibodies, biologics diseases because its potential advantages, low cost, safety, high volume. review summarizes latest advancements plant-derived used combat discusses prospects challenges plant-based agents.

Language: Английский

Vaccine adjuvants: mechanisms and platforms DOI Creative Commons
Tingmei Zhao,

Yulong Cai,

Yujie Jiang

et al.

Signal Transduction and Targeted Therapy, Journal Year: 2023, Volume and Issue: 8(1)

Published: July 19, 2023

Abstract Adjuvants are indispensable components of vaccines. Despite being widely used in vaccines, their action mechanisms not yet clear. With a greater understanding the by which innate immune response controls antigen-specific response, adjuvants’ beginning to be elucidated. can categorized as immunostimulants and delivery systems. Immunostimulants danger signal molecules that lead maturation activation antigen-presenting cells (APCs) targeting Toll-like receptors (TLRs) other pattern recognition (PRRs) promote production antigen signals co-stimulatory signals, turn enhance adaptive responses. On hand, systems carrier materials facilitate presentation prolonging bioavailability loaded antigens, well antigens lymph nodes or APCs. The systematically summarized at this review. This is followed an introduction mechanisms, properties, progress classical vaccine adjuvants. Furthermore, since some adjuvants under investigation exhibit potency than adjuvants, could compensate for deficiencies summary adjuvant platforms subsequently presented. Notably, we highlight different immunological properties these platforms, will provide wide range options rational design basis, review points out development prospects problems should paid attention future.

Language: Английский

Citations

328
Efficacy of SARS-CoV-2 vaccines and the dose–response relationship with three major antibodies: a systematic review and meta-analysis of randomised controlled trials DOI Creative Commons
Zhirong Yang,

Yiwen Jiang,

Fu-Xiao Li

et al.

The Lancet Microbe, Journal Year: 2023, Volume and Issue: 4(4), P. e236 - e246

Published: Feb. 28, 2023

Summary

Background

The efficacy of SARS-CoV-2 vaccines in preventing severe COVID-19 illness and death is uncertain due to the rarity data individual trials. How well antibody concentrations can predict also uncertain. We aimed assess these infections different severities dose–response relationship between efficacy.

Methods

did a systematic review meta-analysis randomised controlled trials (RCTs). searched PubMed, Embase, Scopus, Web Science, Cochrane Library, WHO, bioRxiv, medRxiv for papers published Jan 1, 2020 Sep 12, 2022. RCTs on were eligible. Risk bias was assessed using tool. A frequentist, random-effects model used combine common outcomes (ie, symptomatic asymptomatic infections) Bayesian rare hospital admission, infection, death). Potential sources heterogeneity investigated. relationships neutralising, spike-specific IgG receptor binding domain-specific titres with examined by meta-regression. This registered PROSPERO, CRD42021287238.

Findings

28 (n=286 915 vaccination groups n=233 236 placebo groups; median follow-up 1–6 months after last vaccination) across 32 publications included this review. combined full 44·5% (95% CI 27·8–57·4) infections, 76·5% (69·8–81·7) 95·4% credible interval 88·0–98·7) hospitalisation, 90·8% (85·5–95·1) 85·8% (68·7–94·6) death. There against but insufficient evidence suggest whether could differ according type vaccine, age vaccinated individual, between-dose (p>0·05 all). Vaccine infection waned over time vaccination, an average decrease 13·6% 5·5–22·3; p=0·0007) per month be enhanced booster. found significant non-linear each (p<0·0001 all), there remained considerable efficacy, which cannot explained concentrations. risk low most studies.

Interpretation

higher than milder infection. wanes Higher are associated estimates precise predictions difficult large unexplained heterogeneity. These findings provide important knowledge base interpretation application future studies issues.

Funding

Shenzhen Science Technology Programs.

Language: Английский

Citations

91
Plant-based biopharmaceutical engineering DOI Open Access
Lukas Eidenberger, Benjamin Kogelmann, Herta Steinkellner

et al.

Nature Reviews Bioengineering, Journal Year: 2023, Volume and Issue: 1(6), P. 426 - 439

Published: March 21, 2023

Language: Английский

Citations

75
Platforms, advances, and technical challenges in virus-like particles-based vaccines DOI Creative Commons
Reeshu Gupta, Kajal Arora, Sourav Singha Roy

et al.

Frontiers in Immunology, Journal Year: 2023, Volume and Issue: 14

Published: Feb. 9, 2023

Viral infectious diseases threaten human health and global stability. Several vaccine platforms, such as DNA, mRNA, recombinant viral vectors, virus-like particle-based vaccines have been developed to counter these diseases. Virus-like particles (VLP) are considered real, present, licensed successful against prevalent emergent due their non-infectious nature, structural similarity with viruses, high immunogenicity. However, only a few VLP-based commercialized, the others either in clinical or preclinical phases. Notably, despite success phase, many still struggling small-scale fundamental research owing technical difficulties. Successful production of on commercial scale requires suitable platform culture mode for large-scale production, optimization transduction-related parameters, upstream downstream processing, monitoring product quality at each step. In this review article, we focus advantages disadvantages various VLP-producing recent advances challenges VLP current status candidates commercial, preclinical, levels.

Language: Английский

Citations

62
The role of vaccines in the COVID-19 pandemic: what have we learned? DOI Creative Commons
Florian Krammer

Seminars in Immunopathology, Journal Year: 2023, Volume and Issue: 45(4-6), P. 451 - 468

Published: July 12, 2023

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged late in 2019 and caused the disease (COVID-19) pandemic that has so far claimed approximately 20 million lives. Vaccines were developed quickly, became available end of 2020, had a tremendous impact on protection from SARS-CoV-2 mortality but with emerging variants morbidity was diminished. Here I review what we learned COVID-19 vaccinologist's perspective.

Language: Английский

Citations

41
Fast-track development of vaccines for SARS-CoV-2: The shots that saved the world DOI Creative Commons
Vivek P. Chavda, Qian Yao, Lalitkumar K. Vora

et al.

Frontiers in Immunology, Journal Year: 2022, Volume and Issue: 13

Published: Oct. 3, 2022

In December 2019, an outbreak emerged of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) which leads to disease 2019 (COVID-19). The World Health Organisation announced the a global health emergency on 30 January 2020 and by 11 March it was declared pandemic. spread severity took heavy toll overburdening system, particularly since there were no available drugs against SARS-CoV-2. With immediate worldwide effort, communication, sharing data, large amounts funding, researchers pharmaceutical companies immediately fast-tracked vaccine development in order prevent disease, hospitalizations death. A number vaccines quickly approved for use, vaccination rollouts put place. However, due several individuals being hesitant vaccinations many poorer countries not having access vaccines, multiple SARS-CoV-2 variants that distinct from original variant. Uncertainties related effectiveness various new as well specific-side effects have remained concern. Despite these uncertainties, fast-track approval, manufacturing at scale, effective distribution COVID-19 remain topmost priorities around world. Unprecedented efforts made developers/researchers healthcare staff, played major role distributing shots provided protection and/or reduced severity, deaths, even with delta omicron variants. Fortunately, those who become infected, appears protect hospitalisation, fatality COVID-19. Herein, we analyse ongoing studies platforms saved deaths

Language: Английский

Citations

47
Does the World Still Need New Covid-19 Vaccines? DOI Open Access
Hanna Nohynek, Annelies Wilder‐Smith

New England Journal of Medicine, Journal Year: 2022, Volume and Issue: 386(22), P. 2140 - 2142

Published: May 4, 2022

Language: Английский

Citations

46
Adjuvant physiochemistry and advanced nanotechnology for vaccine development DOI
Hongze Ren,

Wencong Jia,

Yujie Xie

et al.

Chemical Society Reviews, Journal Year: 2023, Volume and Issue: 52(15), P. 5172 - 5254

Published: Jan. 1, 2023

This review provides an introduction of basic principles adjuvanted human vaccines in clinics and summarizes emerging nanotechnology adjuvants vaccine development against cancer infectious diseases.

Language: Английский

Citations

35
A review of SARS-CoV-2 variants and vaccines: Viral properties, mutations, vaccine efficacy, and safety DOI Creative Commons
Md. Aminul Islam

Infectious Medicine, Journal Year: 2023, Volume and Issue: 2(4), P. 247 - 261

Published: Sept. 13, 2023

The severe acute respiratory syndrome coronavirus disease 2 instigated by of 2019 (COVID-19) has delivered an unfathomable obstruction that touched all sectors worldwide. Despite new vaccine technologies and mass administration booster doses, the virus persists, unknown ending pandemic for variants sub-variants. Moreover, whether leaning on home medications or using plant extracts is sufficient often to combat generated tremendous interest in scientific fraternity. Different databases including PubMed, Scopus, Web Science, Google Scholar used find published articles linked with related topics. Currently, COVID-19 third fourth shots vaccines are progressively administered worldwide, where some countries trail others a significant margin. Many proteins viral activity have changed, possibly boosting infectivity making antibodies ineffective. This study will reminisce genome, associated pathways protein functions, variants, their mutations. current, comprehensive review also provide information developed several biotech companies efficacy costs boosters level. As no working protect fully against proactive research needs be conducted based sub-lineage,

Language: Английский

Citations

25
Synthetic biology for plant genetic engineering and molecular farming DOI
Yunqing Wang, Gözde S. Demirer

Trends in biotechnology, Journal Year: 2023, Volume and Issue: 41(9), P. 1182 - 1198

Published: April 1, 2023

Language: Английский

Citations

24